Client was a small biopharmaceutical start-up that had recently IPO’ed with one product in their pipeline
Client had recently completed two phase 3 studies, with both studies demonstrating efficacy and safety of new drug
An analyst science day was organized to communicate efficacy and safety to the investor community
Challenge
Data to communicate was in raw, non-digital form, with no slides made for presentation
Key opinion leaders to be identified as presenters to investors because of existing reputation and influence in medical field
Client had minimal experience in communicating new clinical data to a large investor audience
Resolution
For a publicly traded company, Xelay Acumen developed and organized content and presentations for Science Day with financial analyst community, including coordination with with external speakers, 2 days after primary data presented as a late-breaking oral presentation for the first time